GeneSystem Co

GeneSystem Co Stock-Based Compensation

The Stock-Based Compensation (SBC) of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is 223.37 M KRW. In the previous year, Stock-Based Compensation (SBC) was 64.12 M KRW — a change of 248.37% (higher).

Stock-Based Compensation

223.37 MKRW

YoY

248.37%

Last updated:

Stock-Based Compensation (SBC) of GeneSystem Co is 2025 223.37 M KRW. Stock-Based Compensation (SBC) of GeneSystem Co was 2024 64.12 M KRW. It decreases by 248.37% higher compared to the previous year.

The GeneSystem Co Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
321.20 M KRW
Jan 1, 2021
80.30 M KRW
Jan 1, 2022
80.15 M KRW
Jan 1, 2023
106.87 M KRW
Jan 1, 2024
64.12 M KRW
Jan 1, 2025
223.37 M KRW
The GeneSystem Co Stock-Based Compensation history
YEARStock-Based CompensationYoY
223.37 MKRW+248.37%
64.12 MKRW-40.00%
106.87 MKRW+33.33%
80.15 MKRW-0.19%
80.30 MKRW-75.00%
321.20 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

Stock-Based Compensation (SBC) of GeneSystem Co is 223.37 M KRW in 2025.

Stock-Based Compensation (SBC) of GeneSystem Co changed from 64.12 M KRW to 223.37 M KRW, representing a 248.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s GeneSystem Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GeneSystem Co

All Key Metrics — GeneSystem Co